# A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis

> **NCT03029455** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 163 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-659
- **DRUG:** Tezacaftor
- **DRUG:** Ivacaftor
- **DRUG:** VX-659 Matching Placebo
- **DRUG:** Triple Combination (TC) Matching Placebos

## Key facts

- **NCT ID:** NCT03029455
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2017-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03029455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03029455, "A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03029455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*